A quiet but potentially major shift is building inside the federal health apparatus. Robert F. Kennedy Jr. is pushing to make peptides more accessible, and the Food and Drug Administration is preparing to revisit restrictions that have kept many of these compounds on the sidelines since 2023. If the upcoming July review goes Kennedy’s way, a wide range of peptide injections could soon move out of regulatory limbo and into mainstream availability. Supporters see a...
For decades, scientists believed that cognitive decline was an unavoidable part of aging. Memory loss, brain fog, and slower thinking were seen as the natural result of a lifetime of wear and tear. But a groundbreaking discovery from Texas A&M University is now challenging that assumption in a dramatic way....
A quiet but potentially major shift is building inside the federal health apparatus. Robert F. Kennedy Jr. is pushing to make peptides more accessible, and the Food and Drug Administration is preparing to revisit restrictions that have kept many of these compounds on the sidelines since 2023. If the upcoming July review goes Kennedy’s way, a wide range of peptide injections could soon move out of regulatory limbo and into mainstream availability. Supporters see a...
A quiet but potentially major shift is building inside the federal health apparatus. Robert F. Kennedy Jr. is pushing to make peptides more accessible, and the Food and Drug Administration is preparing to revisit restrictions that have kept many of these compounds on the sidelines since 2023. If the upcoming July review goes Kennedy’s way, a wide range of peptide injections could soon move out of regulatory limbo and into mainstream availability. Supporters see a...